Literature DB >> 8328376

Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction.

N Oldridge1, W Furlong, D Feeny, G Torrance, G Guyatt, J Crowe, N Jones.   

Abstract

Although there are extensive clinical evaluations of cardiac rehabilitation after acute myocardial infarction (AMI), no full economic evaluation is available. Patients with AMI and mild to moderate anxiety or depression, or both, while still in hospital were randomized to either an 8-week rehabilitation intervention (n = 99) or usual care (n = 102). Comprehensive costs and health-related quality of life, measured with the time trade-off preference score, were obtained in a 12-month trial, and together with survival data derived from published meta-analyses, cost-utility and cost-effectiveness of early cardiac rehabilitation were estimated. The best estimate of the incremental net direct 12-month costs for patients randomized to rehabilitation was $480 (United States, 1991)/patient. During 1-year follow-up, rehabilitation patients had fewer "other rehabilitation visits" (p < 0.0001) and gained 0.052 quality-adjusted life-year more than did the group with usual care. The cost-utility ratio was $9,200/quality-adjusted life-year gained with cardiac rehabilitation during the year of follow-up. This economic evaluation of cardiac rehabilitation does not consider the important distinctions between affordability and worth of alternative health-care services. The data provide evidence that brief cardiac rehabilitation initiated soon after AMI for patients with mild to moderate anxiety or depression, or both, is an efficient use of health-care resources and may be economically justified.

Entities:  

Mesh:

Year:  1993        PMID: 8328376     DOI: 10.1016/0002-9149(93)90152-3

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  32 in total

Review 1.  Coronary disease. Management of the post-myocardial infarction patient: rehabilitation and cardiac neurosis.

Authors:  D R Thompson; R J Lewin
Journal:  Heart       Date:  2000-07       Impact factor: 5.994

Review 2.  The limited incorporation of economic analyses in clinical practice guidelines.

Authors:  Joel F Wallace; Scott R Weingarten; Chiun-Fang Chiou; James M Henning; Andriana A Hohlbauch; Margaret S Richards; Nicole S Herzog; Lior S Lewensztain; Joshua J Ofman
Journal:  J Gen Intern Med       Date:  2002-03       Impact factor: 5.128

3.  Cardiac rehabilitation.

Authors:  J Dinnes; J Kleijnen; M Leitner; D Thompson
Journal:  Qual Health Care       Date:  1999-03

4.  Rehabilitation and secondary prevention in patients with cardiovascular diseases.

Authors:  G Maisano; G Molinis; D Tuniz; M Valente
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 5.  Methods for measuring temporary health States for cost-utility analyses.

Authors:  Davene R Wright; Eve Wittenberg; J Shannon Swan; Rebecca A Miksad; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

6.  Cardiac rehabilitation in the United Kingdom: guidelines and audit standards. National Institute for Nursing, the British Cardiac Society and the Royal College of Physicians of London.

Authors:  D R Thompson; G S Bowman; A L Kitson; D P de Bono; A Hopkins
Journal:  Heart       Date:  1996-01       Impact factor: 5.994

7.  Images in cardiology. Cardiac sarcoidosis.

Authors:  R Zimmermann; A Haunstetter; W Kübler
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

8.  The evidence base for the cost effectiveness of cardiac rehabilitation.

Authors:  R Taylor; B Kirby
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

Review 9.  Narrative review comparing the benefits of and participation in cardiac rehabilitation in high-, middle- and low-income countries.

Authors:  Karam I Turk-Adawi; Sherry L Grace
Journal:  Heart Lung Circ       Date:  2014-11-29       Impact factor: 2.975

Review 10.  Cardiac rehabilitation past, present and future: an overview.

Authors:  Warner M Mampuya
Journal:  Cardiovasc Diagn Ther       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.